MMP9 and neoplasm: ADAMTS-1 is anti-angiogenic, whereas MMP9 is highly pro-angiogenic, and can trigger the ‘angiogenic switch’, a process in tumours where the balance of pro- and anti-angiogenic factors swings towards a pro-angiogenic outcome (Bergers et al., 2000).